205 related articles for article (PubMed ID: 25096504)
1. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
2. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
[TBL] [Abstract][Full Text] [Related]
3. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Chen W; Wang H; Wei H; Gu S; Wei H
J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
[TBL] [Abstract][Full Text] [Related]
6. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
7. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan.
Takahashi M; Fujita M; Asai N; Saki M; Mori A
Expert Opin Pharmacother; 2018 Oct; 19(15):1635-1642. PubMed ID: 30281377
[TBL] [Abstract][Full Text] [Related]
9. The safety of istradefylline for the treatment of Parkinson's disease.
Müller T
Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
Mizuno Y; Kondo T;
Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
[TBL] [Abstract][Full Text] [Related]
11. Istradefylline for the treatment of Parkinson's disease.
Park A; Stacy M
Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
[TBL] [Abstract][Full Text] [Related]
12. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
Wang XL; Feng ST; Chen B; Hu D; Wang ZZ; Zhang Y
Neurosci Lett; 2022 Mar; 774():136515. PubMed ID: 35149201
[TBL] [Abstract][Full Text] [Related]
15. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
[TBL] [Abstract][Full Text] [Related]
16. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
17. The effect of istradefylline for Parkinson's disease: A meta-analysis.
Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
[TBL] [Abstract][Full Text] [Related]
18. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.
Kondo T; Mizuno Y;
Clin Neuropharmacol; 2015; 38(2):41-6. PubMed ID: 25768849
[TBL] [Abstract][Full Text] [Related]
19. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Müller T
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
Yabe I; Kitagawa M; Takahashi I; Matsushima M; Sasaki H
Clin Neuropharmacol; 2017; 40(6):261-263. PubMed ID: 28976411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]